



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :

Andreas NANDY et al.

Serial No. : 10/583,089

Filed : June 15, 2006

For : DNA SEQUENCE, AND RECOMBINANT PREPARATION OF GROUP 4  
MAJOR ALLERGENS FROM CEREALS

**SUBMISSION OF PRIORITY DOCUMENT(S)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith is a certified copy of each of the below-identified document(s),  
benefit of priority of each of which is claimed under 35 U.S.C. § 119:

COUNTRY	APPLICATION NO.	FILING DATE
GERMANY	103 59 351.9	December 16, 2003

Acknowledgment of the receipt of the above document(s) is requested.

No fee is believed to be due in association with this filing, however, the Commissioner is hereby authorized to charge fees under 37 C.F.R. §§ 1.16 and 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/Anthony J. Zelano/

Anthony J. Zelano, Reg. No. 27,969  
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3178

Date: March 25, 2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the matter of an application for a German Patent

with the file reference 103 59 351.9

filed on 16 December 2003

in the name of Merck Patent GmbH, Darmstadt, Germany,

and in the matter of an application for a United States Patent.


I, Dr. Ashwood Stephen DRANE, B.Sc., Ph.D., BDÜ, translator to SD Translations Ltd. of Beechwood, Chivery, Tring, Hertfordshire, HP23 6LD, England, do solemnly and sincerely declare:

1. That I am a citizen of the United Kingdom of Great Britain and Northern Ireland.
2. That I am well acquainted with the German and English languages and am a competent translator thereof.
3. That the following is to the best of my knowledge and belief a true and correct translation of the above-referenced patent application and the Official Certificate attached thereto

Dated this 2nd day of March 2009



Dr. Ashwood Stephen Drane



# FEDERAL REPUBLIC OF GERMANY

---



## Priority certificate regarding the filing of a patent application

**File reference:** 103 59 351.9

**Date of filing:** 16 December 2003

**Applicant/proprietor:** Merck Patent GmbH,  
64293 Darmstadt/DE

**Title:** DNA sequence, and recombinant  
preparation of group 4 major allergens  
from cereals

**IPC:** C 07 K, C 12 N, A 61 K

The attached pages are a correct and accurate reproduction of the original documents of this patent application.

Seal

Munich, 16 September 2004  
**German Patent and Trademark Office**  
On behalf of  
**The President**

[signature]

**Ebert**

**Merck Patent Gesellschaft  
mit beschränkter Haftung  
64271 Darmstadt**

**DNA sequence, and recombinant preparation of  
group 4 major allergens from cereals**

## **DNA sequence, and recombinant preparation of group 4 major allergens from cereals**

5

### **Background of the invention**

10

The present invention relates to the provision of DNA sequences of group 4 major allergens from cereals (*Triticeae*). The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for *in vitro* and *in vivo* diagnosis of pollen allergies.

15

20

Type 1 allergies are of importance worldwide. Up to 20% of the population in industrialised countries suffer from complaints such as allergic rhinitis, conjunctivitis or bronchial asthma. These allergies are caused by allergens present in the air (aeroallergens) which are released by sources of various origin, such as plant pollen, mites, cats or dogs. Up to 40% of these type 1 allergy sufferers in turn exhibit specific IgE reactivity with grass pollen allergens, inter alia cereal pollen allergens (Freidhoff et al., 1986, J. Allergy Clin. Immunol. 78, 1190-2001). Of the cereal pollen allergens, the allergens of rye have particular importance.

25

30

35

The substances which trigger type 1 allergy are proteins, glycoproteins or polypeptides. After uptake via the mucous membranes, these allergens react with the IgE molecules bonded to the surface of mast cells in sensitised individuals. If two IgE molecules are crosslinked to one another by an allergen, this results in the release of mediators (for example histamine,

- 2 -

prostaglandins) and cytokines by the effector cell and thus in the corresponding clinical symptoms.

5 A distinction is made between major and minor allergens, depending on the relative frequency with which the individual allergen molecules react with the IgE antibodies of allergy sufferers.

10 The allergens from the pollen of various species from the family of the grasses (*Poaceae*) are divided into groups which are homologous amongst one another.

In particular, the molecules of major allergen group 4 have high immunological cross-reactivity with one another both with monoclonal murine antibodies and also with human IgE antibodies (Fahlbusch et al., 1993 Clin. Exp. Allergy 23:51-60; Leduc-Brodard et al., 1996, J. Allergy Clin. Immunol. 98:1065-1072; Su et al., 1996, J. Allergy Clin. Immunol. 97:210; Fahlbusch et al., 1998, Clin. Exp. Allergy 28:799-807; Gavrovic-Jankulovic et al., 2000, Invest. Allergol. Clin. Immunol. 10 (6):361-367; Stumvoll et al. 2002, Biol. Chem. 383:1383-1396; Grote et al., 2002, Biol. Chem. 383:1441-1445; Andersson and Lidholm, 2003, Int. Arch. Allergy Immunol. 130:87-107; Mari, 2003, Clin. Exp. Allergy, 33 (1):43-51).

25 A complete DNA sequence is hitherto not known for any of the group 4 major allergens.

30 From the group 4 allergen from *Dactylus glomerata*, it has hitherto only been possible for peptides to be obtained by enzymatic degradation and sequenced:

DIYNYMEPYVSK,

VDPTDYFGNEQ,

ARTAWVDSGAQLGELSY

35 and GVLFNIQYVNYWFAP (Leduc-Brodard et al., 1996, J. Allergy Clin. Immunol. 98: 1065-1072).

- 3 -

Peptides have also been obtained from the group 4 allergen of sub-tropical Bermuda grass (*Cynodon dactylon*) by proteolysis and sequenced:

KTVKPLYIITP,

5

KQVERDFLTSLTKDIPQLYLKS,

TVKPLYIITPITAAMI,

LRKYGTAADNVIDAKVWDAQGRLL,

KWQTVAPALPDPNM,

VTWIESVPYIPMGDK,

10

GTVRDLLXRTSNIKAFGKY,

TSNIKAFGKYKSDYVLEPIPKKS,

YRDLDLGVNQVVG,

SATPPTHRSGVLFNI

15

and AAAALPTQVTRDIYAFMTPYVSKNPRQAYVNYRDLD (Liaw et al., 2001, Biochem. Biophys. Research Communication 280: 738-743).

20

For *Lolium perenne*, peptide fragments having the following sequences have been described for the basic group 4 allergen: FLEPVLGLIFPAGV and GLIEFPAGV (Jaggi et al., 1989, Int. Arch. Allergy Appl. Immunol. 89: 342-348).

25

As the first sequence of a group 4 allergen, the still unpublished sequence of Phl p 4 from *Phleum pratense* has been elucidated by the inventors of the present patent application and described in International Application PCT/EP03/06092.

30

Nothing is hitherto known on the sequences of the group 4 major allergens from cereals (*Triceae*).

35

The object on which the present invention was based therefore consisted in the provision of DNA sequences of group 4 major allergens from cereals, in particular the allergen Sec c 4 from rye (*Secale cereale*), Hor v 4 from barley

- 4 -

5 (*Hordeum vulgare*) and Tri a 4 from wheat (*Triticum aestivum*) and of corresponding recombinant DNA molecules on the basis of which the allergens can be expressed as protein and made available, as such or in modified form, for pharmacologically significant exploitation. The sequence of Phl p 4 was the starting point for the present invention.

#### 10 **List of sequences according to the invention**

15 The DNA and protein sequences of the mature allergens are preceded by a signal sequence shown in italics and underlined. The respective stop codons in the DNA sequences are shown underlined. The encoding region ends with them.

**Figure 1:** DNA sequence of Sec c 4. (a) Isoform Sec c 4.01, (b) isoform Sec c 4.02.

20 **Figure 2:** Protein sequences derived from the DNA sequences in accordance with Fig. 1.

25 **Figure 3:** DNA sequence of Hor v 4.

**Figure 4:** Protein sequence derived from the DNA sequence in accordance with Fig. 3.

30 **Figure 5:** DNA sequence of Tri a 4. (a) Isoform Tri a 4.01, (b) isoform Tri a 4.02.

35 **Figure 6:** Protein sequences derived from the DNA sequences in accordance with Fig. 5.



- 5 -

**Figure 7:** DNA sequence of Phl p 4, in accordance with SEQ ID NO 5 from PCT/EP03/06092.

5 **Figure 8:** Protein sequence of Phl p 4, in accordance with SEQ ID NO 6 from PCT/EP03/06092.

10 **Description of the invention**

The present invention now provides for the first time DNA sequences of the cereal pollen major allergens Sec c 4, Hor v 4 and Tri a 4, as shown in Figs. 1, 3 and 5.

15 The present invention therefore relates to DNA molecules selected from the nucleotide sequences depicted in Figs. 1, 3 and 5.

20 The invention furthermore relates to sequences homologous to the DNA sequences according to the invention and corresponding DNA molecules of group 4 allergens from other *Poaceae*, such as, for example, *Lolium perenne*, *Dactylis glomerata*, *Poa pratensis*, *Cynodon dactylon* and *Holcus lanatus*, which, owing to the sequence homology that exists, hybridise with the DNA sequences according to the invention under stringent conditions,  
25 or have immunological cross-reactivity with respect to the allergens according to the invention.

30 The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action.

35 The invention therefore furthermore relates to corresponding partial sequences, a combination of partial sequences, or replacement, elimination or addition mutants which encode an immunomodulatory, T-cell-reactive fragment of a group 4 allergen from the *Poaceae*.

5 With knowledge of the DNA sequence of the naturally occurring allergens, it is now possible to prepare these allergens as recombinant proteins which can be used in the diagnosis and therapy of allergic diseases (Scheiner and Kraft, 1995, *Allergy* 50: 384-391).

10 A classical approach to effective therapeutic treatment of allergies is specific immunotherapy or hyposensitisation (Fiebig, 1995, *Allergo J.* 4 (6): 336-339, Bousquet et al., 1998, *J. Allergy Clin. Immunol.* 102 (4): 558-562). In this method, the patient is injected subcutaneously with natural allergen extracts in increasing doses. However, there is a risk in this method of allergic reactions or even anaphylactic shock. In order to minimise these  
15 risks, innovative preparations in the form of allergoids are employed. These are chemically modified allergen extracts which have significantly reduced IgE reactivity, but identical T-cell reactivity compared with the untreated extract (Fiebig, 1995, *Allergo J.* 4 (7): 377-382).

20 Even more substantial therapy optimisation would be possible with allergens prepared by recombinant methods. Defined cocktails of high-purity allergens prepared by recombinant methods, optionally matched to the individual sensitisation patterns of the patients, could replace extracts from natural allergen sources since these, in addition to the various allergens,  
25 contain a relatively large number of immunogenic, but non-allergenic secondary proteins.

Realistic perspectives which may result in reliable hyposensitisation with expression products are offered by specifically mutated recombinant allergens in which IgE epitopes are specifically deleted without impairing the  
30 T-cell epitopes which are essential for therapy (Schramm et al., 1999, *J. Immunol.* 162: 2406-2414).

35 A further possibility for therapeutic influencing of the disturbed TH cell equilibrium in allergy sufferers is immunotherapeutic DNA vaccination, which involves treatment with expressible DNA which encodes the relevant

- 7 -

allergens. Initial experimental evidence of allergen-specific influencing of the immune response has been furnished in rodents by injection of allergen-encoding DNA (Hsu et al., 1996, Nature Medicine 2 (5): 540-544).

5 The present invention therefore also relates to a DNA molecule described above or below as medicament and to a corresponding recombinant expression vector as medicament.

10 The corresponding proteins prepared by recombinant methods can be employed for therapy and for *in vitro* and *in vivo* diagnosis of pollen allergies.

For preparation of the recombinant allergen, the cloned nucleic acid is  
15 ligated into an expression vector, and this construct is expressed in a suitable host organism. After biochemical purification, this recombinant allergen is available for detection of IgE antibodies by established methods.

20 The present invention therefore furthermore relates to a recombinant expression vector comprising a DNA molecule described above or below, functionally linked to an expression control sequence, and a host organism transformed with said DNA molecule or said expression vector.

25 The invention also relates to the use of at least one DNA molecule described above or at least one expression vector described above for the preparation of a medicament for the immunotherapeutic DNA vaccination of patients with allergies in the triggering of which group 4 allergens from  
30 the *Poaceae*, preferably *Triticeae*, in particular Sec c 4, Hor v 4, Tri a 4, are involved and/or for the prevention of such allergies.

As already stated, the invention can be used as an essential component in  
35 a recombinant allergen- or nucleic acid-containing preparation for specific immunotherapy. A number of possibilities arise here. On the one hand, the protein with an unchanged primary structure may be a constituent of the

- 8 -

5 preparation. On the other hand, a hypoallergenic (allergoid) form can be used in accordance with the invention for therapy in order to avoid undesired side effects by specific deletion of IgE epitopes of the molecule as a whole or the production of individual fragments which encode T-cell epitopes. Finally, the nucleic acid per se, if ligated with a eukaryotic expression vector, gives a preparation which, when applied directly, modifies the allergic immune state in the therapeutic sense.

10 The present invention furthermore relates to the polypeptides encoded by one or more of the DNA molecules described above, preferably in their property as medicament.

15 These are proteins corresponding to one of the amino acid sequences depicted in Figs. 2, 4 and 6. In particular, these are the mature proteins (without signal sequence component), beginning with amino acid 23 in the case of the amino acid sequences depicted in Figs. 2 and 4 and with amino acid 22 in the case of the amino acid sequences depicted in Fig. 6. The invention furthermore relates to proteins which contain these amino acid sequences or parts of these sequences.

20 The invention accordingly also relates to a process for the preparation of such polypeptides by cultivation of a host organism and isolation of the corresponding polypeptide from the culture.

25 The invention likewise relates to the use of at least one polypeptide described above for the preparation of a medicament for the diagnosis and/or treatment of allergies in the triggering of which group 4 allergens from the *Poaceae*, preferably *Triticeae*, in particular Sec c 4, Hor v 4, Tri a 4, are involved and for the prevention of such allergies.

30 When determining the protein and DNA sequences according to the invention, the following procedure was followed:

Sec c 4 from rye

5 1. Starting from the DNA sequence of Phl p 4 (PCT/EP03/06092), specific primers (Table 1) derived from the Phl p 4 sequence were generated. Five clones were obtained from rye pollen DNA by PCR with primers #87 and #83. The amplified Sec c 4 gene fragment 1 corresponding to these clones encodes a polypeptide corresponding to amino acids 68-401 of Phl p 4  
10 (Fig. 8

15 2. An EST database search was carried out with the partial Sec c 4 sequence. However, no homologous sequences were found in EST databases specialising in rye. Instead, individual, homologous, non-overlapping EST fragments were found in EST databases specialising in barley and wheat. Individual EST fragments extend into the 5'-UTR region and others into the 3'-UTR region (UTR = untranslated region) of the corresponding  
20 genes.

25 3. However, a complete group 4 gene from wheat or barley cannot be constructed from the EST sequences found in the databases since these sequences do not overlap and a homologous group 4 gene is not known. However, it was possible to assign these EST sequences with reference to the Phl p 4 sequence (Fig. 7) and the Sec c 4 fragment obtained in step 1 and these served as template for the preparation of PCR primers.

30 4. With the aid of primers #195 and #189 prepared in this way, three clones were obtained by PCR. Primer #195 was derived from a barley EST sequence, primer #189 is a Phl p 4-specific primer and overlaps the Phl p 4 stop codon and the codons of the 10 C-terminal Phl p 4 amino acids. The  
35 Sec c 4 gene fragment 2 amplified in this way encodes a polypeptide, beginning within the signal sequence and ending with the position

- 10 -

corresponding to position 490 of Phl p 4. This polypeptide covers the N terminal of Sec c 4.

5 5a. Three further clones were obtained by PCR with primers #195 and #202. Both primers were derived from barley EST sequences. The amplified Sec c 4 gene 3 encodes the corresponding amino acids beginning within the signal sequence and ending at the C terminal of Sec c 4. The complete sequence of mature Sec c 4 is thus present in the sequence  
10 determined.

The next two steps 5b and 5c serve to double-check the result obtained in step 5a:

15 5b. A further clone was obtained by PCR with primers #195 and #203. Primer #195 was derived from a barley EST sequence, primer #203 from a wheat EST sequence. The amplified Sec c 4 gene encodes the corresponding amino acids beginning within the signal sequence and ending at  
20 the C terminal of Sec c 4. The complete sequence of mature Sec c 4 is therefore present in the sequence determined.

25 5c. A further clone was obtained by PCR with primers #195 and #198. The amplified Sec c 4 gene encodes the corresponding amino acids beginning within the signal sequence and ending at the C terminal of Sec c 4. The complete sequence of mature Sec c 4 is therefore present in the sequence  
30 determined.

35 Two isoforms Sec c 4.01 and 4.02 were found. The mature allergens begin at the points indicated in Figs. 1 and 2.

- 11 -

#### Hor v 4 from barley

With the aid of the Sec c 4 sequences obtained as described above, homologous EST fragments were found in EST databases of *Hordeum vulgare*. These fragments overlap, but not to give a complete gene. With reference to the EST sequences found, however, it was possible to generate Hor v 4-specific primers, which were used for amplification of the Hor v 4 gene from genomic DNA.

In total, 15 clones were analysed.

4 clones were obtained by PCR with primers #195 and #198.

4 clones were obtained by PCR with primers #195 and #202.

3 clones were obtained by PCR with primers #194 and #198.

4 clones were obtained by PCR with primers #194 and #202.

The derived protein sequence begins within the signal sequence of Hor v 4 and extends to the C-terminal end of the protein.

#### Tri a 4 from wheat

With the aid of the Sec c 4 sequences obtained as described above, homologous EST fragments were found in EST databases of *Triticum aestivum*. These fragments overlap, but not to give a complete gene. With reference to the EST sequences found, however, it was possible to generate the Tri a 4-specific primers #199, #203, #204 and #206, which were used for amplification of the Tri a 4 gene from genomic DNA.

In total, 13 clones were analysed.

4 clones were obtained by PCR with primers #204 and #203.

4 clones were obtained by PCR with primers #204 and #199.

3 clones were obtained by PCR with primers #206 and #203.

4 clones were obtained by PCR with primers #206 and #199.

- 12 -

The derived protein sequences begin within the signal sequence of Tri a 4 and extend to the C-terminal end of the protein.

Two variants Tri a 4.01 and Tri a 4.02 were found.

5

In order to prepare the recombinant allergens according to the invention, the DNA sequences in accordance with Figs. 1, 3 and 5 were incorporated into expression vectors (for example pProEx, pSE 380). *E. coli*-optimised codons were used for the N-terminal amino acids known from the protein sequencing.

10

After transformation in *E. coli*, expression and purification of the recombinant allergens according to the invention by various separation techniques, the proteins obtained were subjected to a refolding process.

15

Both allergens can be employed for highly specific diagnosis of grass pollen allergies. This diagnosis can be carried out *in vitro* by detection of specific antibodies (IgE, IgG1 - 4, IgA) and reaction with IgE-loaded effector cells (for example basophiles from blood) or *in vivo* by skin test reactions and provocation at the reaction organ.

20

The reaction of the allergens according to the invention with T-lymphocytes from grass pollen allergy sufferers can be detected by allergen-specific stimulation of the T-lymphocytes for proliferation and cytokine synthesis both with T-cells in freshly prepared blood lymphocytes and also on established nSec c 4, nHor v 4 or nTri a 4-reactive T-cell lines and clones.

25

The triplets encoding the cysteines were modified by site-specific mutagenesis in such a way that they encode other amino acids, preferably serine. Both variants in which individual cysteines have been replaced and those in which various combinations of 2 cysteine residues or all cysteines have been modified were prepared. The expressed proteins of these cys-

30

35



- 13 -

teine point mutants have greatly reduced or zero reactivity with IgE antibodies from allergy sufferers, but react with the T-lymphocytes from these patients.

5 The present invention therefore furthermore relates to a DNA molecule described above or below in which one, a plurality of or all the cysteine residues of the corresponding polypeptide have been replaced with another amino acid by site-specific mutagenesis.

10 The immunomodulatory activity of hypoallergenic fragments which correspond to polypeptides having T-cell epitopes and that of the hypoallergenic point mutants (for example cysteine replacements) can be detected by their  
15 reaction with T-cells from grass pollen allergy sufferers.

Such hypoallergenic fragments or point mutants of the cysteines can be employed as preparations for hyposensitisation of allergy sufferers since  
20 they react with the T-cells with equal effectiveness, but result in reduced IgE-mediated side effects owing to the reduced or entirely absent IgE reactivity.

25 If the nucleic acids encoding the hypoallergenic allergen variants according to the invention or the unmodified DNA molecules according to the invention are ligated with a human expression vector, these constructs can likewise be used as preparations for immunotherapy (DNA vaccination).

30 Finally, the present invention relates to pharmaceutical compositions comprising at least one DNA molecule described above or at least one expression vector described above and optionally further active ingredients and/or adjuvants for the immunotherapeutic DNA vaccination of patients with  
35 allergies in the triggering of which group 4 allergens from the *Poaceae*, preferably *Triticeae*, in particular Sec c 4, Hor v 4, Tri a 4, are involved and/or for the prevention of such allergies.

A further group of pharmaceutical compositions according to the invention comprises at least one polypeptide described above instead of the DNA and is suitable for the diagnosis and/or treatment of said allergies.

5

Pharmaceutical compositions in the sense of the present invention comprise, as active ingredients, a polypeptide according to the invention or an expression vector and/or respective pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios. The active ingredients according to the invention can be brought into a suitable dosage form here together with at least one solid, liquid and/or semi-liquid excipient or adjuvant and optionally in combination with one or more further active ingredients.

10

15

Particularly suitable adjuvants are immunostimulatory DNA or oligonucleotides having CpG motives.

20

These compositions can be used as therapeutic agents or diagnostic agents in human or veterinary medicine. Suitable excipients are organic or inorganic substances which are suitable for parenteral administration and do not adversely affect the action of the active ingredient according to the invention. Suitable for parenteral use are, in particular, solutions, preferably oil-based or aqueous solutions, furthermore suspensions, emulsions or implants. The active ingredient according to the invention may also be lyophilised and the resultant lyophilisates used, for example, for the preparation of injection preparations. The compositions indicated may be sterilised and/or comprise adjuvants, such as preservatives, stabilisers and/or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances and/or a plurality of further active ingredients.

25

30

35

Furthermore, sustained-release preparations can be obtained by corresponding formulation of the active ingredient according to the invention – for example by adsorption on aluminium hydroxide.

The invention thus also serves for improving *in vitro* diagnosis as part of allergen component-triggering identification of the patient-specific sensitisation spectrum. The invention likewise serves for the preparation of significantly improved preparations for the specific immunotherapy of grass pollen allergies.

**Table 1 Primers used**

a) Sec c 4

Primer number	Sequence
#0083	GGCTCCCGGGGCGAACCAGTAG
#0087	ACCAACGCCTCCCACATCCAGTC
#0189	GATAAGCTTCTCGAGTGATTAGTACTTTTTGATCAGCG GCGGGATGCTC
#0195	GCTCTCGATCGGCTACAATGGCG
#0198	CACGCACTACAAATCTCCATGCAAG
#0202	CATGCTTGATCCTTATTCTACTAGTTGGGC
#0203	TACGCACGATCCTTATTCTACTAGTTGGGC

a) Hor v 4

Primer number	Sequence
#0194	GCCTTGTCCTGCCACCACGCCGCCGCCACC
#0195	GCTCTCGATCGGCTACAATGGCG
#0198	CACGCACTACAAATCTCCATGCAAG
#0202	CATGCTTGATCCTTATTCTACTAGTTGGGC

c) Tri a 4

Primer number	Sequence
#0199	CACGCACTAAATCTCCATGCAAG
#0203	TACGCACGATCCTTATTCTACTAGTTGGGC
#0204	AAGCTCTATCGCCTACAATGGCG
#0206	GGTGCTCCTCTTCTGCGCCTTGTCC

## Patent Claims

- 5 1. A DNA molecule corresponding to a nucleotide sequence selected from one of the sequences depicted in Figures 1, 3 and 5.
- 10 2. A DNA molecule which hybridises with a DNA molecule according to Claim 1 under stringent conditions and originates from DNA sequences from *Poaceae* species.
- 15 3. A DNA molecule, encoding a polypeptide, which cross-reacts immunologically with the major allergens Sec c 4, Hor v 4 or Tri a 4 from *Secale cereale*, *Hordeum vulgare* or *Triticum aestivum* and originates from DNA sequences from *Poaceae* species.
- 20 4. A DNA molecule, corresponding to a partial sequence or a combination of partial sequences according to one or more of Claims 1 to 3, which encodes an immunomodulatory, T-cell-reactive fragment of a group 4 allergen from the *Poaceae*.
- 25 5. A DNA molecule, corresponding to a nucleotide sequence according to one or more of Claims 1 to 4, encoding an immunomodulatory T-cell-reactive fragment, characterised in that said nucleotide sequence has been specifically modified by specific mutation of individual codons, elimination or addition.
- 30 6. A DNA molecule according to Claim 5, characterised in that the said mutation results in the replacement of one, a plurality of or all cysteines of the corresponding polypeptide with another amino acid.
- 35 7. A recombinant DNA expression vector or a cloning system comprising a DNA molecule according to one or more of Claims 1 to 6, functionally

- 17 -

linked to an expression control sequence.

- 5
8. A host organism transformed with a DNA molecule according to one or more of Claims 1 to 6 or an expression vector according to Claim 7.
- 10
9. A process for the preparation of a polypeptide encoded by a DNA sequence according to one or more of Claims 1 to 6 by cultivation of a host organism according to Claim 8 and isolation of the corresponding polypeptide from the culture.
- 15
10. A polypeptide corresponding to one of the amino acid sequences depicted in Figures 2, 4 and 6, which is encoded by a DNA sequence according to one or more of Claims 1 to 6.
- 20
11. A polypeptide in accordance with one of the amino acid sequences depicted in Figs. 2, 4 and 6, corresponding to the mature allergen, selected from the following group of amino acid sequences
- one of the amino acid sequences depicted in Figures 2 and 4 beginning with amino acid 23,
  - one of the amino acid sequences depicted in Fig. 6 beginning with amino acid 22.
- 25
12. A polypeptide according to Claim 10 or 11 as medicament.
- 30
13. A pharmaceutical composition comprising at least one polypeptide according to Claim 12 and optionally further active ingredients and/or adjuvants for the diagnosis and/or treatment of allergies in the triggering of which group 4 allergens from the *Poaceae* are involved.
- 35
14. Use of at least one polypeptide according to Claim 12 for the preparation of a medicament for the diagnosis and/or treatment of allergies in the triggering of which group 4 allergens from the *Poaceae* are involved

- 18 -

and/or for the prevention of such allergies.

5

15. A DNA molecule according to one or more of Claims 1 to 6 as medicament.

16. A recombinant expression vector according to Claim 7 as medicament.

10

17. A pharmaceutical composition comprising at least one DNA molecule according to Claim 15 or at least one expression vector according to Claim 16 and optionally further active ingredients and/or adjuvants for the immunotherapeutic DNA vaccination of patients with allergies in the triggering of which group 4 allergens from the *Poaceae* are involved and/or for the prevention of such allergies.

15

20

18. Use of at least one DNA molecule according to Claim 15 or at least one expression vector according to Claim 16 for the preparation of a medicament for the immunotherapeutic DNA vaccination of patients with allergies in the triggering of which group 4 allergens from the *Poaceae* are involved and/or for the prevention of such allergies.

25

30

35

### Abstract

5

10

15

20

25

30

35

The present invention relates to the provision of DNA sequences of group 4 major allergens from cereals. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for *in vitro* and *in vivo* diagnosis of pollen allergies.

## Figures

### 5 Figure 1(a)

AACTATAGGGCCTTCGCGCTGGCGCTCCTCTTCTGCGCCTTGTCCTG  
CCAAGCCGCGCGGCGCCTACGCGCCCGTGCTGCCAAGGCGGACT  
10 TCCTCGGATGCCTCATGAAGGAGATACCGGCCCGCCTCCTCTACGCC  
AAGAGCTCGCCTGACTACCCACCGTGCTGGCGCAGACCATCAGGAA  
CTCGCGGTGGTCGTCGCCGCAGAACGTGAAGCCGATCTACATCATCA  
CCCCACCAACGCCTCGCACATCCAGTCCGCGGTGGTGTGCGGCCGC  
15 CGGCACGGCATCCGCCTCCGCGTGCGGAGCGGCGGCCACGACTACGA  
GGGCCTGTGCTACCGGTCTGAGAAACCCGAGACGTTCCGCCGTGCTCG  
ACCTCAACAAGATGCGGGCAGTGTGCGGTGACGGCTACGCCCGCACG  
GCGTGGGTGGAATCCGGCGCGCAGCTCGGCGAGCTCTACTACGCGAT  
20 CGCCAAGAACAGCCCCGTGCTCGCGTTCCCGGCTGGCGTCTGCCCGT  
CCATCGGCGTCGGCGGCAACTTCGCAGGCGGCGGCTTTGGCATGCTG  
CTGCGCAAGTACGGCATCGCCGCTGAGAACGTCATCGACGTCAAGGT  
GGTCGACCCCAACGGCAAGCTGCTCGACAAGAGCTCCATGAGCGCGG  
25 ACCACTTCTGGGCCGTTAGGGGCGGCGGCGGAGAGAGCTTTGGCATC  
GTCGTCTCGTGGCAGGTGAAGCTCCTGCCGGTGCTCCCAACCGTGAC  
CGTGCTCAAGATCCCCAAGACGGTGCAAGAAGGCGCCATAGACCTCG  
TCAACAAGTGGCAGCTGGTCGGGCCGGCACTTCCCGGCGACCTCATG  
30 ATCCGCATCATCCTTGCCGGGAACAGCGCGACGTTTCGAGGCCATGTA  
CCTGGGCACCTGCAGTACCCTGACGCCGCTGATGAGCAGCAAATTCC  
CCGAGCTTGGCATGAACCCCTCGCACTGCAACGAGATGTCCTGGATC  
AAGTCCATCCCCTTCATCCACCTCGGCAAGCAGAACCTCGACGACCT  
CCTCAACCGGAACAACACCTTCAAACCATTCGCCGAATACAAGTCGG  
35 ACTACGTGTACCAGCCCTTCCCCAAGCCCGTGTGGGAGCAGATCTTC



- 21 -

GGCTGGCTTGTGAAGCCCGGCGCGGGGATCATGATCATGGACCCCTA  
TGGCGCCACCATCAGCGCTACCCCCGAAGCGGCGACGCCGTTCCCTC  
ACCGCCAGGGCGTCCCTCTTCAACATCCAGTACGTCAACTACTGGTTC  
5 GCTGAGTCAGCCGGCGCGGCGCCGCTGCAGTGGAGCAAGGACATATA  
CAAGTTCATGGAGCCGTACGTGAGCAAAAATCCCAGGCAGGCGTATG  
CCAACTACAGGGACATCGACCTTGGCAGGAATGAGGTGGTGAACGAC  
ATCTCCACCTACAGCAGCGGCAAAGTGTGGGGTGAGAAGTACTTCAA  
10 GGGCAACTTCCAAAGGCTCGCCATTACCAAGGGCAAGGTGGATCCTC  
AGGACTACTTCAGGAACGAGCAGAGCATCCCGCCACTGGTCGAGAAG  
TACTGATCGAGGACCTTGCATGGAAATTTAGTGCGTGGTTGGCGTTT  
CACAT

15

**Figure 1(b)**

AACTCGAGGGCCTTTGCTCTGGTGCCCCCTCCTCATCTGCGTCTTGTC  
20 CTGCCACGCCGCGCTCTCCTACGCGGCGGCGCCGGTGCCGGCCAAGG  
AGGACTTCTTCGGATGCCTGGTGAAGGAGATACCGGCCCGCCTCCTC  
TACGCCAAGAGCTCGCCTGCCTTCCCCACCGTCCTGGCGCAGACCAT  
CAGGAACTCGCGGTGGTCGTCGCCGCAGAGCGTGAAGCCGCTCTACA  
25 TCATCACCCCCACCAACGCCTCCCACATCCAGTCCGCGGTGGTGTGC  
GGCCGCCGGCACGGCGTCCGCATCCGCGTGCGGAGCGGCGGCCACGA  
CTACGAGGGCCTGTCTGTAACCGGTCCGAGCGCCCCGAGGCGTTCGCCG  
TCGTGACCTCAACAAGATGCGGGCCGTGGTGGTCGACGGCAAGGCT  
30 CGCACGGCGTGGGTGGACTCCGGTGCGCAGCTCGGCGAGCTCTACTA  
CGCCATCGCCAAGAAGAGCCCCGTGCTCGCGTTCCCGGCCGGCGTTT  
GCCCCGACCATTGGTGTAGGCGGCAACTTCGCTGGCGGCGGCTTCGGC  
ATGCTGCTGCGCAAGTACGGCATCGCCGCCGAGAACGTCATCGACGT  
35 GAAGGTGGTCGACGCCAACGGCACACTGCTCGACAAGAGCTCCATGA

- 22 -

5  
10  
15  
20  
25

GCGCGGATCACTTCTGGGCCGTCAGGGGCGGCGGCGGAGAGAGCTTC  
GGCATCGTTCGTGTCGTGGCAGGTGAAGCTCCTCCCGGTGCCTCCAC  
CGTGACCGTGTTCAAGATCCCCAAGACGGTGCAAGAAGGCGCCGTAG  
AGCTCATCAACAAGTGGCAGCTAGTCGCGCCGGCCCTCCCCGACGAC  
CTGATGATCCGCATCATCGCTTTCGGCGGCACCGCCAAGTTCGAGGC  
CATGTACCTGGGCACCTGCAAAGCCCTGACACCGCTGATGAGCAGCA  
GATTCCCCGAGCTCGGCATGAACGCCTCGCACTGCAACGAGATGCCC  
TGGATCAAGTCCGTCCCATTTCATCCACCTTGGCAAGCAGGCCACCCT  
CTCCGACCTCCTCAACCGGAACAACACCTTCAAACCCTTCGCCGAGT  
ACAAGTCGGACTACGTCTACCAGCCCGTCCCCAAGCCCGTCTGGGCG  
CAGATCTTCGTCTGGCTCGTCAAACCCGGCGCCGGGATCATGGTCAT  
GGACCCCTACGGCGCCGCCATCAGCGCCACCCCCGAAGCCGCCACGC  
CGTTCCTCACC GCAAGGACGTCTCTTCAACATCCAGTACGTCAAC  
TACTGGTTCGACGAGGCAGGCGGCGCCGCGCCGCTGCAGTGGAGCAA  
GGACATGTACAGGTTCATGGAGCCGTACGTCAGCAAGAACCC CAGAC  
AGGCCTACGCCAACTACAGGGACATCGACCTCGGCAGGAACGAGGTG  
GTCAACGACATCTCCACCTATGCCAGCGGCAAGGTCTGGGGCGAGAA  
GTACTTCAAGGGCAACTTCCAAAGGCTCGCCATTACCAAGGGCAAGG  
TGGATCCTCAGGACTACTTCAGGAACGAGCAGAGCATCCCGCCGCTG  
CTAGGGAAAGTAGTAGTACTCTTGCTTGCATGGAGATTTGTAGTGCCT  
CTTTCGCGTTTCAAATGCCCAACTAGTAGAATAAGGATCGTGCGTA

**Figure 2(a)**

30  
35

NYRAFALALLFCALSCQAAAAAYAPVPAKADFLGCLMKEIPARLLYA  
KSSPDYPTVLAQTIRNSRWSSPQNVKPIYIITPTNASHIQSAVVCGR  
RHGIRLRVRSGGHDYEGLSYRSEKPETFAVVDLNKMRAVSVDGYART  
AWVESGAQLGELYAIAKNSPVLAFPAGVCPSIGVGGNFAGGGFGML

- 23 -

LRKYGIAAENVIDVKVVDPNGKLLDKSSMSADHFWAVRGGGGESFGI  
VVSQVQVKKLLPVPPTVTVLKI PKTVQEGAILVNKWQLVGPALPGDLM  
IRIILAGNSATFEAMYLGTCTLTPLMSSKFPELGMNPSHCNEMSWI  
5 KSIPFIHLGKQNLDDLLNRNNTFKPFAEYKSDYVYQPFKPVWEQIF  
GWLVKPGAGIMIMDPYGATISATPEAATPFPHRQGVLFNIQYVNYWF  
AESAGAAPLQWSKDIYKFMEPYVSKNPRQAYANYRDIDLGRNEVVND  
ISTYSSGKVGGEKYFKGNFQRLAITKGKVDPODYFRNEQSIPLVEK  
10 Y

**Figure 2(b)**

15 NSRAFALVPLLICVLSCHAAVSYAAAPVPAKEDFFGCLVKEIPARLL  
YAKSSPAFPTVLAQTIRNSRWSSPQSVKPLYIITPTNASHIQSAVVC  
GRRHGVRI RVRSGGHDYEGLSYRSEPEAFVVDLNKMRAVVVDGKA  
RTAWVDSGAQLGELYAIAKNSPVLAFPAGVCPTIGVGGNFAGGGFG  
20 MLLRKYGIAAENVIDVKVVDANGTLLDKSSMSADHFWAVRGGGGESF  
GIVVSWQVKKLLPVPPTVTVFKI PKTVQEGAVELINKWQLVAPALPDD  
LMIRIIAFGGTAKFEAMYLGTCKALTPLMSSRFPELGMNASHCNEMP  
WIKSVPFHLGKQATLSDLLNRNNTFKPFAEYKSDYVYQVPVKPVWA  
25 QIFVWLVKPGAGIMVMDPYGAAISATPEAATPFPHRKDVLFNIQYVN  
YWFDEAGGAAPLQWSKDMYRFMEPYVSKNPRQAYANYRDIDLGRNEV  
VNDISTYASGKVGGEKYFKGNFQRLAITKGKVDPODYFRNEQSIPL  
LGK

30

35

**Figure 3**

AGCTCGAGGGCCTTCGCTCTGGTGCTCCTCCTCTGCGCCTTGTCCTG  
CCACCACGCTGCCGTCTCCTCCGCGCAGGTGCCGGCCAAGGACGACT  
5 TCCTGGGATGCCTCGTGAAGGAGATACCGGCCCCGCCTCCTCTTCGCC  
AAGAGCTCGCCTGCCTTCCCCGCCGTCTGGAGCAGACCATCAGGAA  
CTCGCGGTGGTTCGTGCGCCGAGAACGTGAAGCCGCTCTACATCATCA  
10 CCCCCACCAACACCTCCCACATCCAGTCTGCTGTGGTGTGCGGCCGC  
CGGCACGGCGTCCGCCTCCGCGTGCGGAGCGGCGGCCACGACTACGA  
GGGCCTGTTCGTACCGGTCCGAGCGCCCCGAGGCGTTCGCCGTCTAG  
ACCTCAACAAGATGCGGACCGTGTTGGTCAACGAAAAGGCCCGCACG  
GCGTGGGTGGACTCCGGCGCGCAGCTCGGCGAGCTCTACTACGCCAT  
15 CGCCAAGAACAGCCCCGTGCTCGCGTTCCCAGCCGGCGTTTGCCCGT  
CCATTGGTGTAGGTGGCAACTTCGCTGGCGGCGGCTTCGGCATGCTG  
CTGCGCAAGTACGGCATCGCCGCCGAGAACGTCATCGACGTCAAGCT  
GGTCGACGCCAACGGCAAGCTGCTCGACAAGAGCTCCATGAGCCCGG  
20 ACCACTTCTGGGCCGT CAGGGGCGGCGGCGGAGAGAGCTTCGGCATC  
GTCGTCTCGTGGCAGGTGAAGCTTCTCCCGGTGCCTCCCACCGTGAC  
TGTGTTTCAGATCCCCAAGACAGTGCAAGAAGGCGCCGTAGACCTCA  
TCAACAAGTGGCAGCTGGTCGCGCCGGGCCCTTCCCGGCGACATCATG  
25 ATCCGCATCATCGCCATGGGGGACAAAGCGACGTTTCGAGGCCATGTA  
CCTGGGCACCTGCAAAACCCTGACGCCGCTGATGAGCAGCAAATTCC  
CGGAGCTTGGCATGAACCCCTCGCACTGCAACGAGATGCCCTGGATC  
AAGTCCATCCCCTTCATCCACCTTGGCAAGCAGGCCACCCTGGCCGA  
30 CCTCCTCAACCGGAACAACACCTTCAAACCCTTCGCCGAATACAAGT  
CGGACTACGTCTACCAGCCCGTCCCCAAGCCCGTGTGGGAGCAGCTC  
TTCGGCTGGCTCACGAAACCCGGCGCGGGGATCATGGTCATGGACCC  
ATACGGCGCCACCATCAGCGCCACCCCCGAAGCGGCGACGCCGTTCC  
35 CTCACCGCAAGGGCGTCCTCTTCAACATCCAGTACGTCAACTACTGG

- 25 -

5 TTCGCCGAGGCAGCCGGCGCCGCGCCGCTGCAGTGGAGCAAGGACAT  
TTACAAATTCATGGAGCCGTTTCGTGAGCAAGAACCCAGGCAGGCGT  
ACGCCAACTACAGGGACATCGACCTCGGCAGGAACGAGGTGGTGAAC  
GACATCTCAACCTACAGCAGCGGCAAGGTGTGGGGCGAGAAGTACTT  
CAAGGGCAACTTCCAAAGGCTCGCCATCACCAAGGGCAAGGTGGATC  
CCCAGGACTACTTCAGGAACGAGCAGAGCATCCCGCCGCTGCTGGGC  
AAGTAGTGACCGAGAGTCTTGCATGGAGATTTGTAGTGCCTGCTTGG  
10 CGTTTCTGAT

**Figure 4**

15 SSRAFALVLLLCALSCHHAAVSSAQVPAKDDFLGCLVKEIPARLLFA  
KSSPAFPVLEQTIRNSRWSSPQNVKPLYIITPTNTSHIQSAVVCGR  
RHGVRLRVRSGGHDYEGLSYRSEPEAFVVDLNKMRTVLVNEKART  
AWVDSGAQLGELYAIAKNSPVLAFFPAGVCPSIGVGGNFAGGGFGML  
20 LRKYGIAAENVIDVKLVDANGKLLDKSSMSPDHFVAVRGGGGESFGI  
VVSQVKLLPVPPTVTVFQIPKTVQEGAVDLINKWQLVAPALPGDIM  
IRIIAMGDKATFEAMYLGTCKTLTPLMSSKFPELGMNPSHCNEMPWI  
KSIPFIHLGKQATLADLLNRNNTFKPFAEYKSDYVYQVPKPVWEQL  
25 FGWLTKPGAGIMVMDPYGATISATPEAATPFPHRKGVLFNIQYVNYW  
FAEAAGAAPLQWSKDIYKFMEPFVSKNPRQAYANYRDIDLGRNEVVN  
DISTYSSGKVWGEKYFKGNFQRLAITKGKVDPQDYFRNEQSIPPLLG  
K

30

35

**Figure 5(a)**

AACTATAGGGCCTTCACGCTGGTGCTCCTCTTCTGCGCCTTGTCCTG  
TCAAGCCGCCGCCACCTACGCGCCGGTGCCCTGCCAAGGAGGACTTCC  
5 TCGGATGCCTCATGAAGGAGATAACGGGCACGCCTCCTCTACGCCAAG  
AGCTCGCCTGACTTCCCCACCGTCCTGGCGCAGACCATCAGGAACTC  
GCGGTGGTTGTGCGCCGACGAAACGTGAAGCCGCTCTACATCATCACCC  
CCACCAACGCCTCGCACATCCAGTCCGCGGTGGTGTGCGGACGCCGG  
10 CACAGCGTCCGCCTCCGCGTCCGGAGCGGCGGCCACGACTACGAGGG  
CCTGTGCTACCGGTCCGAGAAACCCGAGACGTTGCGCGTCGTCGACC  
TCAACAAGATGCGGGCAGTGTTGATCGACGGCTACGCCCCGCACGGCG  
TGGGTCGAATCCGGCGCGCAGCTCGGCGAGCTCTACTACGCCATCGC  
15 GAAAAACAGCCCCGTGCTCGCGTTCCCGGCCGGCGTCTGCCCCGACCA  
TCGGCGTTCGGCGGCAACTTCGCAGGCGGCGGCTTTGGCATGCTGCTG  
CGGAAGTACGGCATCGCCGCCGAGAACGTCATCGACGTCAAGGTGGT  
CGACCCCAACGGCAAGCTTCTCGACAAGAGCTCCATGAGCCCGGACC  
20 ACTTCTGGGCCGTCAGGGGCGGCGGCGGAGAGAGCTTTGGCATCGTC  
GTGTGCTGGCAAGTGAAGCTCCTGCCGGTGCCCTCCCACCGTGACCGT  
GTTCAAGATCCCCAAGACAGTGCAAGAAGGCGCCGTAGACCTCGTCA  
ACAAGTGGCAACTGGTCGGGCGCGGCCCTTCCCGGCGACCTCATGATC  
25 CGCGTCATCGCTGCGGGGAACACCGCGACATTCGAGGGCATGTACCT  
GGGCACCTGCCAAACCCTGACGCCGTTGATGAGCAGCCAATTCCCCG  
AGCTTGGCATGAACCCCTATCACTGCAACGAGATGCCCTGGATCAAG  
TCCATCCCCTTCATCCACCTCGGCAAAGAGGCCAGCCTGGTCGACCT  
30 CCTCAACCGGAACAACACCTTCAAGCCCTTCGCCGAATACAAGTCGG  
ACTACGTGTACCAGCCCTTCCCCAAGCCCGTGTGGGAGCAGATCTTC  
GGCTGGCTCACGAAGCCCGGTGGGGGGATGATGATCATGGACCCATA  
CGGCGCCACCATCAGCGCCACCCCCGAAGCGGCGACGCCGTTCCCTC  
35 ACCGCCAGGGCGTTCTCTTCAACATCCAGTACGTCAACTACTGGTTC

- 27 -

5 GCCGAGGCAGCCGCCGCCGCCGCTGCAGTGGAGCAAGGACATGTA  
CAATTTTCATGGAGCCGTACGTGAGCAAGAACCCCAAGGCAGGCGTACG  
CCA ACTACAGGGACATTGACCTCGGCAGGAACGAGGTGGTGAACGAC  
ATCTCAACCTATAGCAGCGGCAAGGTTTGGGGCGAGAAGTACTTCAA  
GGGCAACTTCCAAAGGCTCGCTATTACCAAGGGCAAGGTGGATCCTC  
AGGACTACTTCAGGAACGAGCAGAGCATCCCGCCGCTGCTCGAGAAG  
TACTGATCGAGGACCTTGCATGGAGATTTAGTGCGTGGTTGCCGTTT  
CACAT

**Figure 5(b)**

15 AACTGTAGGGCCTTCGCGCAGGTGCTCCTCTTCTTCGCCTTGTCCTG  
CCAAGCCGCCGCCACCTACGCGCCGGTGCCTGCCAAGGAGGACTTCC  
TCGGATGCCTCATGAAGGAGATACCGGCCCGCCTCCTCTACGCCAAG  
AGCTCGCCTGACTACCCACCGTGCTGGCGCAGACCATCAGGAACTC  
20 GCGGTGGTTCGACGCAGCAGAACGTGAAGCCGCTGTACATCATCACC  
CCACCAACGCCTCCCACATCCAATCCGCGGTGGTGTGCGGCCGCCGG  
CACGGCGTCCGCCTCCGCGTGCGGAGCGGCGGCCACGACTACGAGGG  
CCTGTTCGTACCGGTCCGAGAAACCCGAGACGTTCCGCCGTCGTTCGACC  
25 TCAACAAGATGCGGGCAGTGGTTGTCGACGGCTACGCCCCGCACGGCG  
TGGGTCTGAATCCGGCGCGCAGCTCGGCGAGCTCTACTACGCCATCGC  
GAAGAACAGCCCCGTGCTCGCGTTCCCGGCCGGCGTCTGCCCCGTCCA  
TCGGCGTCCGGCGGCAACTTCGCAGGCGGCGGCTTCGGCATGCTGCTG  
30 CGCAAGTACGGCATCGCCGCCGAGAACGTCATCGACGTCAAGGTGGT  
CGACCCCGACGGCAAGCTGCTCGACAAGAGCTCCATGAGCGCGGACC  
ACTTCTGGGCCGTCAGGGGCGGCGGCGGAGAGAGCTTCGGCATCGTC  
GTCTCGTGGCAGGTGAAGCTCATGCCAGTGCTCCACCGTCACCGT  
35 GTTTAAGATCCCCAAGACGGTGCAAGAAGGCGCCGTAGACCTCGTCA

- 28 -

ACAAGTGGCAGCTGGTCGGGCGGCACTTCCCGGCGACCTCATGATC  
CGCGTCATCGCTGCCGGGAACACGGCGACGTTCGAGGCCTTGTACCT  
GGGCACCTGCAAAACCCTGACGCCGCTGATGAGCAGCCAATTCCCCG  
5 AGCTTGGCATGAACCCCTATCACTGCAACGAGATGCCCTGGATCAAG  
TCCGTCCCCCTTCATCCACCTCGGCAAACAGGCTGGCCTGGACGACCT  
CCTCAACCGGAACAACACCTTCAAGCCCTTCGCCGAATACAAGTCGG  
ACTACGTGTACCAGCCCTTCCCCAAGCCCGTGTGGGAGCAGATCTTC  
10 GGCTGGCTCGCGAAGCCCGGCGCGGGGATCATGATCATGGACCCCTA  
CGGCGCCACCATCAGCGCCACCCCCGAAGCGGCGACGCCGTTCCCTC  
ACCGCCAGGGCGTCCTCTTCAACATCCAGTATGTCAACTACTGGTTC  
GCCGAGCCAGCCGGCGCCGCGCCGCTGCAGTGGAGCAAGGACATTTA  
15 CAATTTTCATGGAGCCGTACGTGAGCAAGAACCCCAAGGCAGGCGTACG  
CCAACTACAGGGACATCGACCTCGGCAGGAATGAGGTGGTGAACGAC  
ATCTCAACCTACAGCAGCGGCAAGGTGTGGGGCGAGAAGTACTTCAA  
GAGCAACTTCCAAAGGCTCGCCATTACCAAGGGCAAGGTAGATCCTC  
20 AGGACTACTTCAGGAATGAGCAAAGCATCCCGCCGCTGATCGAGAAG  
TACTGATCGAGGACCTTGCATGGAGATTTAGTGCGTGGTTGGCGTTT  
CACAT

25 **Figure 6(a)**

NYRAFTLVLLFCALSCQAAATYAPVPAKEDFLGCLMKEIPARLLYAK  
SSPDFPTVLAQTIRNSRWLSPQNVKPLYIITPTNASHIQSAVVCGRR  
30 HSVRLRVRSGGHDYEGLSYRSEKPETFVVDLNMRAVLIDGYARTA  
WVESGAQLGELYAIAKNSPVLAFPAGVCPTIGVGGNFAGGGFGMLL  
RKYGIAAENVIDVKVVDPNGKLLDKSSMSPDHFWAVRGGGGESFGIV  
VSWQVKLLPVPPTVTVEFKIPKTVQEGAVDLVNKWQLVGPALPGDLMI  
35 RVIAAGNTATFEGMYLGTCQTLTPLMSSQFPELGMNPHYHCNEMPWIK



- 29 -

5 SIPFIHLGKEASLVDLLNRNNTFKPFAEYKSDYVYQFPFKPVWEQIF  
GWLTKPGGGMMIMDPYGATISATPEAATPFPHRQGVLFNIQYVNYWF  
AEAAAAAPLQWSKDMYNFMETPYVSKNPRQAYANYRDIDLGRNEVVND  
ISTYSSGKVGGEKYFKGNFQRLAITKGKVDPODYFRNEQSIPPLLEK  
Y

**Figure 6(b)**

10

NCRAFAQVLLFFALSCQAAATYAPVPAKEDFLGCLMKEIPARLLYAK  
SSPDYPTVLAQTIRNSRWSTQQNVKPLYIITPTNASHIQSAVVCGRR  
HGVRLRVRSGGHDYEGLSYRSEKPETFVVDLNKMRAVVVDGYARTA  
15 WVESGAQLGELYAIAKNSPVLAFPAGVCPSIGVGGNFAGGGFGMLL  
RKYGIAAENVIDVKVVDPDGKLLDKSSMSADHFWAVRGGGGESFGIV  
VSWQVKLMPVPPTVTVFKIPKTVQEGAVDLVNKWQLVGPALPGDLMI  
RVIAAGNTATFEALYLGTCCKTLTPLMSSQFPELGMNPHYHCNEMPWIK  
20 SVPFIHLGKQAGLDDLLNRNNTFKPFAEYKSDYVYQFPFKPVWEQIF  
GWLAKPGAGIMIMDPYGATISATPEAATPFPHRQGVLFNIQYVNYWF  
AEPAGAAPLQWSKDIYNFMETPYVSKNPRQAYANYRDIDLGRNEVVND  
ISTYSSGKVGGEKYFKSNFQRLAITKGKVDPODYFRNEQSIPPLIEK  
25 Y

**Figure 7**

30

tacttcccgcgcgcgcgctgctaaagaagacttcctgggttgccctggt  
taaagaaatcccgcgcgcgtctgttgtagcgcaaactcgtcgcccgcgt  
atccctcagtcctggggcagaccatccggaactcgaggtggtcgctcg  
35 ccggacaacgtgaagccgctctacatcatcacccccaccaacgtctc

- 30 -

ccacatccagtcgcccgtggtgtgcggccgcccacagcgtccgca  
tccgcgtgcgcagcggcgggcacgactacgagggcctctcgtaccgg  
tctttgcagcccagacggttcgcccgtcgtcgacctcaacaagatgcg  
5 ggcggtgtgggtggacggcaaggcccgccacggcgtgggtggactccg  
gcgcgcagctcggcgagctctactacgccatctataaggcgagcccc  
acgctggcggttcccggccggcgtgtgcccgacgatcggagtgggcgg  
caacttcgcggggcggcggccttcggcatgctgctgcgcaagtacggca  
10 tcgccgcgggagaacgtcatcgacgtgaagctcgtcgacgccaacggc  
aagctgcacgacaagaagtccatgggcgacgaccatttctgggcccgt  
caggggcccggggggcgagagcttcggcatcgtggtcgcgtggcagg  
tgaagctcctgccggtgccgcccaccgtgacaatattcaagatctcc  
15 aagacagtgagcgagggcgccgtggacatcatcaacaagtggcaagt  
ggtcgcgcgcagcttcccgcgcgacctcatgatccgcacatcgcgc  
aggggcccgaaggccacgttcgaggccatgtacctcggcacctgcaaa  
accctgacgccgttgatgagcagcaagttcccggagctcggcatgaa  
cccctcccactgcaacgagatgtcatggatccagtcacatccccttcg  
20 tccacctcggccacagggacgccctcgaggacgacctcctcaaccgg  
aacaactccttcaagcccttcgccgaatacaagtccgactacgtcta  
ccagcccttcccgaagaccgtctgggagcagatcctcaacacctggc  
tcgtcaagcccggcgccgggatcatgatcttcgacccctacggcgcc  
25 accatcagcgccaccccggagtcgccacgcccttccctcaccgcaa  
gggcgtcctcttcaacatccagtacgtcaactactgggttcgccccgg  
gagccgcccgcgcgcccctctcgtggagcaaggacatctacaactac  
atggagccctacgtgagcaagaaccccaggcaggcgtacgcaaacta  
30 cagggacatcgacctcggcaggaacgaggtggtcaacgacgtctcca  
cctacgccagcggcaaggtctggggccagaaatacttcaagggcaac  
ttcgagaggctcgccattaccaagggcaaggtcgatcctaccgacta  
cttcaggaacgagcagagcatcccgcgctcatcaaaaagtactga  
35

**Figure 8**

YFPPPAAKEDFLGCLVKEIPPRLLYAKSSPAYPSVLGQTI RNSRWSS  
5 PDNVKPLYIITPTNVSHIQSAVVCGRHRSVRIRVRSGGHDYEGLSYR  
SLQPETFAVVDLNKMRAVWVDGKARTAWVDSGAQLGELY YAIYKASP  
TLAFPAGVCPTIGVGGNFAGGGFGMLLRKYGIAAENVIDVKLVDANG  
KLHDKKSMGDDHFWAVRGGGGESFGIVVAWQVKLLPVPPTVTIFKIS  
10 KTVSEGAVDIINKWQVVAPQLPADLMIRIIAQGPKATFEAMYLGTCK  
TLTPLMSSKFPELGMNPSHCNEMSWIQSIPFVHLGHRDALEDDLNR  
NNSFKPFAEYKSDYVYQFPKTVWEQILNTWLVKPGAGIMIFDPYGA  
TISATPESATPFPHRKGVLFN IQYVNYWFAPGAAAAPLSWSKDIYNY  
15 MEPYVSKNPRQAYANYRDIDLGRNEVVNDVSTYASGKVWGQKYFKGN  
FERLAITKGKVDPTDYFRNEQSIPPLIKKY

20

25

30

35